Introduction
The incidence of prostate cancer is mounting in both the United States and the United Kingdom, the annual rate being 32 per 100 000 person-years. 1 Similar to the western world, the widespread use of prostate-specific antigen (PSA) screening in Asia has also resulted in a surge in the number of patients diagnosed with early-stage prostate cancer. In China, it has been estimated that more than 200 000 cases of prostate cancer are diagnosed annually. 2 For patients with locally confined prostate cancer, radiation therapy is one of the most commonly used treatment modalities. The aim of radiotherapy is to deliver an effective dose of radiation to the prostatic tumour while minimising the injury to surrounding normal tissues. Four randomised controlled trials demonstrated benefits in terms of biochemical control with escalation of radiotherapy dose. [3] [4] [5] [6] However, dose
New knowledge added by this study • Intensity-modulated radiation therapy is effective and safe in the Chinese population.
Implications for clinical practice or policy
• Intensity-modulated radiation therapy should be considered as one of the effective treatment options for clinically localised prostate cancer.
escalation of radiotherapy runs an increased risk of late complications, whenever treatment is delivered by conventional external beam techniques 7, 8 or threedimensional conformal radiotherapy. 9, 10 Recent advances in intensity-modulated radiation therapy (IMRT) have led to an improved efficacy/toxicity profile in the treatment of prostate cancer. Several reports on prostate cancer IMRT demonstrated encouraging biochemical control and favourable treatment-related toxicities compared to conventional techniques. [11] [12] [13] [14] [15] [16] However, those studies enrolled predominantly Caucasian subjects. As there are differences in stage distribution, risk categories, and pre-treatment PSA levels in Asian patients undergoing radiotherapy, 17, 18 it appeared valuable to evaluate the treatment efficacy and toxicity of prostate cancer IMRT in Asian populations.
From May 2001 to November 2009, our centre has treated a cohort of Chinese patients with localised prostate cancer using IMRT. Based on this patient cohort, our current study primarily aimed to evaluate the efficacy and treatment toxicities of IMRT for prostate cancer. The association between clinical factors and toxicities endured was also studied, 19 The recurrence risk was determined according to the National Comprehensive Cancer Network guidelines. 20 The study was approved by the institutional review board of the Chinese University of Hong Kong, and conducted in accordance with the Helsinki Declaration of 1975.
Radiotherapy planning
The treatment schemes were determined by the risk of pelvic nodal metastasis. Patients with a lowerthan-15% risk, as calculated by the Roach formula, 21 received prostate IMRT alone. On the other hand, those with a higher risk received prior whole-pelvic radiotherapy (WPRT) in addition to a prostate IMRT boost.
All patients underwent CT simulation in the supine position, with immobilisation by vaclock or easyfoam; the slices were taken at 3-mm intervals. To reduce discrepancies in bladder volume between simulation and treatment, patients were instructed to drink 300 mL of water 30 minutes before both the CT simulation and the actual treatment. The planning CT data were then transferred to the Cadplan planning system before 2002, and to the Varian Eclipse planning system (Palo Alto, US) thereafter. The clinical target volume (CTV), planning target volume (PTV), bladder, rectum, and bilateral femoral heads were contoured. The whole prostate gland was included in the CTV, as were the proximal two thirds of the seminal vesicles in those at intermediate or high risk. The PTV was the 3-dimensional expansion of the CTV with a 1-cm margin, except at the posterior border where a 6-mm margin was applied.
For the prostate IMRT-alone group, six static fields with equal-spacing field angles were used to deliver 70-76 Gy (2 Gy per fraction) to the PTV. Optimisation was performed with an inverseplanning iterative algorithm, based on a standard template of dose-volume constraint parameters for both the targets and the OARs. To fulfil the planned acceptance criteria, no more than 5% of the PTV would entail less than the prescribed dose, and none of the PTV would entail more than 110% of that dose. The dose limits and parameters for each critical organ were similar to those described in other IMRT reports. All patients were treated with a sliding window technique using 10-20 MV Varian linear accelerators. For WPRT, a conventional 4-field box technique, which encompassed the regional pelvic lymphatics, and the PTV was used to deliver 44 Gy in 22 daily fractions. This was then followed by the prostate IMRT boost, which delivered a further radiation dose to a total dose of 70-76 Gy; the exact dose was determined/limited by the cumulative dose to the OARs.
Hormonal therapy
A course of 3 to 4 months of neoadjuvant androgen deprivation (hormone) therapy (NHT) was recommended for patients with a more-than-15% risk of pelvic nodal metastases. 22 Such NHT was also used when the prostate gland was considered too bulky for upfront prostate radiotherapy alone. A total of 3 years of adjuvant androgen deprivation (AHT) was recommended for high-risk patients or those within the intermediate risk group, which was at the discretion of individual clinicians. However, not all patients received AHT as recommended because a proportion of them were unable to afford the drug (a self-paid item according to local policy). The typical regimen for both NHT and AHT entailed 3-monthly injections of luteinising hormone-releasing hormone (LHRH) agonist with 2 weeks of flutamide before the first injection.
Dosimetric analysis
The conformity index (CI) and homogeneity index (HI) were calculated for the PTV; the former was calculated using the method described by Paddick. 
Follow-up
Patients were reviewed every week during radiotherapy to monitor them for acute toxicities. Follow-up evaluations after completion of radiotherapy were performed at intervals of 3 to 6 months for at least 5 years; the PSA was determined at every visit. Both acute and late toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 4.02 toxicity scale. Genito-urinary (GU) toxicities included urinary frequency, cystitis, and urinary incontinence, whereas gastro-intestinal (GI) toxicities included proctitis, diarrhoea, abdominal cramps, and faecal incontinence. Post-radiotherapy biochemical failure was defined according to the Phoenix definition (ie elevation of PSA by 2 ng/mL above the nadir). 25 
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (Windows version 17.0.1.80; SPSS Inc, Chicago [IL], US). Continuous variables were expressed as means with standard deviations. Baseline continuous variables were compared using Student's t test and categorical variables by the Chi squared test. The database was frozen on 16 September 2010. Survival curves were constructed using the Kaplan-Meier method and differences were compared using the log-rank test. Clinical factors related to toxicities were examined with the Cox proportional hazards model in the multivariate analysis. The hazard ratio (HR) and the corresponding 95% confidence interval were calculated.
Results

Patients' characteristics
The baseline characteristics of the patient cohort are shown in Table 1 . The median follow-up duration was 44 (range, 7-146) months. The median age at the commencement of treatment was 72 (range, 45-82) years. The median pre-treatment PSA level was 20 (range, 3-440) ng/mL; before treatment 50% of the patients had PSA levels of >20 ng/mL. In our cohort, 12%, 23%, and 65% of the patients belonged to the favourable, intermediate, and unfavourable risk groups, respectively. The median prescribed dose to the prostate PTV was 72 (range, 70-76) Gy. Thirty-six (86%) of the intermediate risk patients received 76 Gy while 43 (36%) of the unfavourable risk patients received a PTV of 76 Gy (Table 1) . A total of 128 (70%) of the patients underwent NHT; the median duration of therapy being 101 (range, 89-132) days. The apparently wide range of NHT therapy durations (11-3660 days) was due to two outliers-the 11-day duration was as a result of one patient who refused subsequent LHRH injections after 11 days of flutamide, while the 3660-day duration was because one patient with localised disease was given 10 years of NHT by doctors from other departments before referral to our clinic.
Treatment efficacy
The median time to the post-radiotherapy PSA nadir was 9.7 months, and the overall survival of the cohort at 5 years was 92%. The 5-year biochemical failurefree survival (BFFS) rates were 95%, 82%, 80% for the favourable, intermediate, and unfavourable risk groups, respectively (P=0.4616; Fig) . Use of AHT in the unfavourable subgroup significantly improved biochemical control as inferred from the univariate analysis (P=0.0094). In the multivariate analysis, early clinical T stage, low pre-treatment PSA level, and the use of AHT were significant prognostic factors for better BFFS (Table 2 ). In contrast, the radiotherapy dose (76 Gy vs <76 Gy) and the use of WPRT were not prognostic factors for BFFS in the univariate or multivariate analyses.
Treatment toxicity
Gastro-intestinal toxicity
Three (2%) of the patients suffered from grade 3 acute GI complications during radiotherapy; none had grade 4 acute GI complications. Eight (4%) patients developed grade 3 late GI complications that manifested as symptomatic rectal bleeding for which they received blood transfusions (Table 3 ). There were no grade 4 late GI complications. Both WPRT and a history of bowel disease were associated with grade 2 or higher acute GI complications (Table  4 ). In the multivariate analysis, the occurrence of acute GI complications was associated with late GI complications (HR=4.497; P=0.026) [ Table 4 ].
Genito-urinary toxicity
In all, 120 (66%) of the patients had grade 1 or 2 acute GU toxicity; none had grade 3 or higher acute GU complications (Table 3) . Grade 3 late GU complications developed in five (3%) patients, two of whom had gross haematuria treated endoscopically and blood transfusions, and another three underwent urethral dilatation for stricture. In the univariate analysis, WPRT was associated with an increased likelihood of developing acute GU toxicities with borderline significance (P=0.0457) [ Table 4 ].
Dosimetric analysis
The mean CI and HI were 1.22 and 1.07, respectively. With respect to OARs, the mean D max , D mean , V 50 , V 60 , V 65 , V 70 and V 75 of the rectum in our cohort were: 75.5 Table 5 ). The D mean of the bladder was significantly higher in patients who had acute GU complications that were grade 2 or higher (52.0 Gy vs 46.8 Gy) [ Table 5 ]. For the late GI or GU complications, there were no significant differences in dosimetric parameters in those with and without grade 2 or higher late complications.
Discussion
In the current study, we demonstrated that prostate IMRT could achieve good biochemical control in a cohort of Chinese patients. The 5-year BFFS rates were 95%, 82%, 80% for the favourable, intermediate, and unfavourable risk groups, respectively. These data were consistent with the results of IMRT series in Caucasians (Table 6) . [11] [12] [13] [14] [15] [16] Our study also concurred with previous reports that Asian patients with prostate cancer tended to present with more advanced or high-risk disease, as evidenced by 88% of the patients having intermediate-or unfavourable-risk disease. Nevertheless, it was evident that ethnicity differences did not influence treatment outcomes.
To the best of our knowledge, the current study is the first to demonstrate that IMRT for prostate cancer is effective in Chinese patients.
Our cohort also showed that the IMRT for prostate cancer is generally well tolerated by Chinese patients. In general, the rates of severe acute toxicities (grade 3 or above according to CTCAE) were lower than 2%. The most frequent were acute GU toxicities, but most were grade 1 to 2 (51 and 15%, respectively) only. Notably, in this study, WPRT was associated with both acute GI and GU toxicities. A possible reason was that the conventional WPRT (4-field box technique) used in our cohort was inefficient in shielding the bowel or bladder. Apart from WPRT, a history of bowel disease was associated with acute GI toxicities, which was also consistent with previous reports. 26, 27 This highlights the importance of a history of bowel disease and cautious planning of radiotherapy so as to minimise acute toxicities.
In the current series, the risk of grade 3 late complications was <5%. However, the proportion of patients experiencing grade 3 late GI complications (4%) was slightly higher than that in other relevant reports. [11] [12] [13] [14] [15] [16] We therefore conducted a comprehensive multivariate analysis to identify clinical factors associated with late GI complications, and found that having an acute GI complication was an independent predictor of late GI complications. This finding was also consistent with previous reports.
28, 29 On the other hand, in the current study, WPRT was not associated with late GI toxicities. Although WPRT could lead to a higher rate of acute GI toxicities, treating them aggressively is the most effective strategy to minimise late GI toxicities.
In the multivariate analysis, AHT was the most significant prognosticator of biochemical control. This finding is compatible with the EORTC study which showed that 3 years of androgen deprivation after external radiation could improve treatment outcomes, especially in patients with an unfavourable risk. 30 In this cohort, 65% of the patients belonged to an unfavourable group. Despite financial limitations, a high proportion (82%) of the patients in the unfavourable group received AHT. Therefore, the association of AHT and better BFFS was less likely to be a chance finding. On the other hand, neither the radiotherapy dose level (76 Gy vs 70 Gy) nor WPRT were prognostic indicators of biochemical control. This was in contrast to the findings of the RTOG 94-13 22 and other doseescalation studies. [3] [4] [5] [6] While the individual effects of AHT, WPRT, and dose escalation are widely acknowledged, the interaction between the three treatment modalities in contributing to the benefits is less well defined in the literature. Further prospective randomised studies are needed to elucidate the interaction of these different treatment modalities used in combination.
We have demonstrated that the V 50 of the rectum is an important parameter in predicting the development of grade 2 or higher acute GI complications. The Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) report and others have emphasised the importance of parameters such as V 70 and V 75 in relation to the probability of complications, but this may pertain more specifically to the situation of the prostate IMRT alone. 31, 32 With the incorporation of WPRT, however, the intermediate dose-volume parameters such as the D mean and V 50 become more relevant in predicting the chance of developing complications. Having saturated the rectum and bladder with almost full tolerance dosing, conventional WPRT becomes a hindrance to dose escalation within the prostate. To overcome this, WPRT delivered by conformal techniques such as the use of IMRT is currently being investigated in many institutions. Ashman et al 33 reported that IMRT-WPRT could significantly reduce irradiation to the small bowel and rectum dosimetrically. Several clinical reports revealed that IMRT-WPRT could significantly reduce treatment-related toxicity in prostate cancer. 34, 35 The previously mentioned limitation in dose escalation after conventional WPRT may be disentangled by improvements in normal tissue sparing with IMRT-WPRT. Furthermore, IMRT-WPRT could potentially reduce the risk of geographically missing pelvic lymph nodes, which was common with conventional WPRT. 36 While the merits of WPRT over prostatealone radiotherapy are still under debate, intensitymodulated WPRT is no doubt the optimal mode of pelvic irradiation from a dosimetric standpoint. 22, [37] [38] [39] One limitation of our study was that it was retrospective, as any attempt to measure the contributory effect of IMRT might be limited by the presence of known or unknown confounders. We therefore tried to conduct a multivariate analysis to evaluate a comprehensive list of putative confounding factors to explore such influences. Secondly, this was a single institution study in a public hospital, so the patient population might be biased towards high-risk disease. However, because of local hospital policies and low recourse to health care insurance in Hong Kong, more than 90% of cancer patients are treated in public hospitals. Thirdly, the multivariate analysis apparently yielded benefit from AHT. Three years of androgen deprivation was shown to be better than 6 months, but the role of extended AHT use beyond 3 years is still unclear. 40 As our follow-up time was relatively short, we were unable to comment on the possibility of late relapse upon withdrawal of AHT.
Conclusion
We demonstrated that IMRT for prostate cancer in Chinese patients can achieve satisfactory biochemical control, while the risk of developing treatmentrelated complications is within an acceptable range. More conformal treatment delivery for WPRT is recommended for safe dose escalation in the course of treating prostate cancer.
